Possible therapeutic applications of single-chain antibodies in systemic autoimmune diseases

Adrienn Angyal, J. Prechl, G. Sármay

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

B cells participate in the induction and maintenance of systemic autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus, via production of pathogenic autoantibodies, contributing to the formation of immune complexes. Immune complex deposition in the kidney and joints causes inflammation and organ destruction, and chemokine production enhances T cell activation and tissue damage. The development of the disorder depends on several factors, for example, genetic susceptibility, environmental factors or immune dysregulation. Traditional therapies, which aimed at the alleviation of symptoms, are giving way to biological therapies with the potential of disrupting disease progression. This article focuses on antibody therapies, especially on the applications of single-chain antibodies, as new biological agents for the treatment of systemic autoimmune disorders.

Original languageEnglish
Pages (from-to)691-704
Number of pages14
JournalExpert Opinion on Biological Therapy
Volume7
Issue number5
DOIs
Publication statusPublished - May 2007

Fingerprint

Single-Chain Antibodies
Antigen-Antibody Complex
Autoimmune Diseases
T-cells
Biological Factors
Chemokines
Autoantibodies
Biological Therapy
Chemical activation
Cells
Immunologic Factors
Genetic Predisposition to Disease
Tissue
Systemic Lupus Erythematosus
Disease Progression
Antibodies
Rheumatoid Arthritis
B-Lymphocytes
Therapeutics
Joints

Keywords

  • Antibody therapy
  • Autoimmunity
  • Inflammation
  • Single-chain fragment variable

ASJC Scopus subject areas

  • Pharmacology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Genetics
  • Immunology

Cite this

Possible therapeutic applications of single-chain antibodies in systemic autoimmune diseases. / Angyal, Adrienn; Prechl, J.; Sármay, G.

In: Expert Opinion on Biological Therapy, Vol. 7, No. 5, 05.2007, p. 691-704.

Research output: Contribution to journalArticle

@article{33c630890c2d42ffb46620ff1221a38f,
title = "Possible therapeutic applications of single-chain antibodies in systemic autoimmune diseases",
abstract = "B cells participate in the induction and maintenance of systemic autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus, via production of pathogenic autoantibodies, contributing to the formation of immune complexes. Immune complex deposition in the kidney and joints causes inflammation and organ destruction, and chemokine production enhances T cell activation and tissue damage. The development of the disorder depends on several factors, for example, genetic susceptibility, environmental factors or immune dysregulation. Traditional therapies, which aimed at the alleviation of symptoms, are giving way to biological therapies with the potential of disrupting disease progression. This article focuses on antibody therapies, especially on the applications of single-chain antibodies, as new biological agents for the treatment of systemic autoimmune disorders.",
keywords = "Antibody therapy, Autoimmunity, Inflammation, Single-chain fragment variable",
author = "Adrienn Angyal and J. Prechl and G. S{\'a}rmay",
year = "2007",
month = "5",
doi = "10.1517/14712598.7.5.691",
language = "English",
volume = "7",
pages = "691--704",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Possible therapeutic applications of single-chain antibodies in systemic autoimmune diseases

AU - Angyal, Adrienn

AU - Prechl, J.

AU - Sármay, G.

PY - 2007/5

Y1 - 2007/5

N2 - B cells participate in the induction and maintenance of systemic autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus, via production of pathogenic autoantibodies, contributing to the formation of immune complexes. Immune complex deposition in the kidney and joints causes inflammation and organ destruction, and chemokine production enhances T cell activation and tissue damage. The development of the disorder depends on several factors, for example, genetic susceptibility, environmental factors or immune dysregulation. Traditional therapies, which aimed at the alleviation of symptoms, are giving way to biological therapies with the potential of disrupting disease progression. This article focuses on antibody therapies, especially on the applications of single-chain antibodies, as new biological agents for the treatment of systemic autoimmune disorders.

AB - B cells participate in the induction and maintenance of systemic autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus, via production of pathogenic autoantibodies, contributing to the formation of immune complexes. Immune complex deposition in the kidney and joints causes inflammation and organ destruction, and chemokine production enhances T cell activation and tissue damage. The development of the disorder depends on several factors, for example, genetic susceptibility, environmental factors or immune dysregulation. Traditional therapies, which aimed at the alleviation of symptoms, are giving way to biological therapies with the potential of disrupting disease progression. This article focuses on antibody therapies, especially on the applications of single-chain antibodies, as new biological agents for the treatment of systemic autoimmune disorders.

KW - Antibody therapy

KW - Autoimmunity

KW - Inflammation

KW - Single-chain fragment variable

UR - http://www.scopus.com/inward/record.url?scp=34248222152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248222152&partnerID=8YFLogxK

U2 - 10.1517/14712598.7.5.691

DO - 10.1517/14712598.7.5.691

M3 - Article

VL - 7

SP - 691

EP - 704

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 5

ER -